We are excited to announce the CNS Diseases Summit, to be held on September 11-12, 2017 in Boston, MA. This meeting provides an interactive learning and relationship-building forum for all players in the CNS field. Colleagues from industry, academia, government agencies, and financing bodies will gather at the interface of research, partnerships, funding, and commercialization to find ways to move forward in a field that has been troubled with clinical failures.
The program will provide a comprehensive look at the current state of CNS, from research to commercialization. Above all, this event will provide networking opportunities in an intimate and accessible environment.
We invite you to join us as we connect, build relationships, and seek new ways forward into the future of CNS research and development.
Joint Plenary Sessions:
I. Opening Keynote Session – Historical Perspective & Current State of the Industry
II. Round Table Discussions: Neuroinflammation, Neuroimaging & Translational Biomarkers
III. Ready, Set, Grow – New Company/Technology Pitch Competition
IV. Award Ceremony & Closing Keynote Session – Predictions for the Future
11th Neurodegenerative Diseases Research & Development
I. Experimental Therapeutics & Approaches in Alzheimer’s Disease & Related Dementias
II. Advances in Parkinson’s Disease Research & Therapeutics
III. Next Frontier in Multiple Sclerosis to Limit or Reverse Neurodegeneration
IV. Therapeutics for Rare & Orphan CNS Disorders
10th CNS Partnering & Deal-making
I. What’s New in CNS – Targets, Models, Assays, etc.
II. Industry Partnering with Academia & CROs to Advance Research
III. CNS Perspectives from Venture Capital & Public Markets
IV. Technology Transfer & Licensing: Challenges & Opportunities
We hope to see you there!
The 2017 Advisory Committee
|2017 Advisory Board Members|
|Mark Allegretta, National Multiple Sclerosis Society|
|Patrick Brundin, Van Andel Research Institute|
|Roopali Gandhi, Harvard Medical School|
|Arti Gaur, Dartmouth Geisel School of Medicine|
|Linda Hedley, Hedley Consulting|
|Ole Isacson, Harvard Medical School|
|Satish Medicetty, GTCbio|
|Katrina Paumier, Michigan State University|
|Suzana Petanceska, National Institute on Aging, NIH|
|Robert Scannevin, Yumanity|
|Malu Tansey, Emory University|
|Harry Tracy, President, NI Research|
|Shafique Virani, BridgeBio|
|Cheryl Wellington, University of British Columbia|
|Iva Toudjarska, Halloran Consulting Group|
|Charles Duncan, Piper Jaffray & Co.|
|Christine Brennan, Novartis Venture Fund|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Merck has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. We’re pursuing some of the most innovative areas in biomedical research emerging today without regard to therapeutic area/modality. Merck has hundreds of successful collaborations with companies, academic institutions, and other organizations. Learn more at www.merck.com/licensing.
At Olympus, we are dedicated to your work, your vision – your science. Our wide range of imaging solutions are built with optical excellence and proven application expertise. Let us be your partner in discovery. Stop by our booth today to see the Olympus IX83 microscope or visit www.olympus-lifescience.com
PsychoGenics, a leading provider of preclinical CNS capabilities offers behavioral testing, electrophysiology, EEG, histology, and microdialysis, along with a variety of transgenic mouse models for dozens of neurodegenerative and psychiatric disorders. PsychoGenics has also pioneered the translation of rodent behavioral responses into robust, high-throughput, high content phenotyping and drug discovery.
SRI International provides collaborative services in translational neuroscience programs involving: sleep /circadian rhythms, cognition, quantitative EEG, memory, addiction, aging, neurodegenerative diseases, pain, MRI /other neuroimaging. SRI applies technical and regulatory expertise to assist clients in advancing drugs /diagnostics efficiently through discovery and development, from “Idea to IND and Beyond”™. www.sri.com/biosciences
Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Renovo Neural Inc. is a specialized preclinical research organization offering services that revolutionize biological research and development of neural therapies. Renovo’s preclinical models for neurodegenerative diseases, customized neurohistology and automated electron microscopy services provide high-quality standard and customizable solutions for basic science, preclinical and clinical research. Renovo provides these specialized research services to pharmaceutical & biotechnology companies, research organizations and academic investigators.